# Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

> **NCT01163227** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- Schizophrenia Disorders

## Interventions

- **DRUG:** Placebo (single and multiple doses)
- **DRUG:** AQW051 2 mg (single and multiple doses)
- **DRUG:** AQW051 15mg (single and multiple doses)
- **DRUG:** AQW051 100mg (single dose), and 50mg (multiple doses)

## Key facts

- **NCT ID:** NCT01163227
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163227, "Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01163227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*